Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : | NSE Symbol : | ISIN : | Industry : |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
02-Dec-2024	06-Dec-2024	AGM	Inter alia, to consider the following items: a) To consider and Approve the Director's Report of the Board of Director of the company for the Financial Year 2023-24. b) To Consider and Approve the date, time, venue and mode for convening the 30th Annual General Meeting of the Company. c) To consider and approve to appoint SBR & Co. LLP, Company Secretaries, as Scrutinizer for the ensuing Annual General Meeting. d) To consider any other business with the permission of the chair Please Find enclosed herewith the Outcome of the Board Meeting dated 06/12/2024 for your reference. (As Per BSE Announcement dated on 06.12.2024)
03-Oct-2024	07-Oct-2024	Quarterly Results	Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/10/2024 inter alia to consider and approve Please find enclosed herewith the Intimation of Board meeting under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations2015 Please find enclosed herewith Outcome of Board Meeting Pusuant to regulation 30 of Sebi ( LODR)Regulation ,2015 held on today i.e. 07th October 2024 (As per BSE Announcement Dated on 07/10/2024)
06-Sep-2024	05-Sep-2024	AGM	Outcome of Board Meeting held on September 05, 2024
23-Jul-2024	29-Jul-2024	Quarterly Results	Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 inter alia to consider and approve Intimation regarding Holding of Board Meeting on 29th July 2024 to consider Un-Audited Financial Results for the quarter ended June 30 2024 Please find enclosed herewith the Un- Audited Standalone financial result for the quarter ended on June 30,2024 . To Considered and approved the standalone Un-Audited financial results of the Company for the quarter ended 30th June, 2024. A copy of the said standalone Un-audited financial results along with the Limited review report from statuary auditor is enclosed herewith (As Per BSE Announcement Dated on: 29/07/2024)
03-May-2024	09-May-2024	Accounts	Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2024 inter alia to consider and approve The Boad meeting of the company will be held Thursday 09th May 2024 Outcome of the Board Meeting is enclosed. (As per BSE Announcement Dated on 09/05/2024)
03-Feb-2024	14-Feb-2024	Quarterly Results	Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 inter alia to consider and approve the Un-Audited Financial Results for the quarter and nine months ended 31st December 2023 Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 ,inter alia, to consider and approve the Un-Audited Financial Results for the quarter and nine months ended 31st December, 2023 (As Per BSE Announcement dated 10.02.2024) Outcome of Board Meeting and Un-Audited Financial Results for the quarter and nine months ended 31st December, 2023 Results - Financial Results for 31.12.2023 Change in Corporate Office Address Change in Directorate Change in Management (As Per BSE Announcement Dated on 14/02/2024)
02-Nov-2023	14-Nov-2023	Quarterly Results	Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve the Un-Audited Financial Results for the quarter and six months ended September 30 2023 Board Meeting Intimation for Rescheduling Of Board Meeting On 14Th November, 2023 Instead Of 08Th November, 2023 To Consider Un-Audited Financial Results For The Quarter And Six Months Ended September 30, 2023 BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 ,inter alia, to consider and approve the Un-Audited Financial Results for the quarter and six months ended September 30, 2023 (As Per BSE Announcement Dated on 08.11.2023) Outcomes of Board Meeting and Un-Audited Financial Results (Standalone) for the Quarter and Six Months ended 30th September, 2023 Reconstitution of Committees (As Per BSE Announcement Dated on 14.11.2023)
04-Sep-2023	04-Sep-2023	AGM	Outcome of Board Meeting
08-Aug-2023	14-Aug-2023	Quarterly Results	Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve the Un-Audited Financial Results for the quarter ended 30th June 2023 Outcomes of Board Meeting and Un-Audited Financial Results (Standalone) for the Quarter and Three Months ended 30th June, 2023 Financial Results for the quarter and three months ended 30.06.2023 Intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015 (As Per BSE Announcement Dated on 14.08.2023)
30-Jun-2023	30-Jun-2023	Change in Directors	Outcome of Board Meeting Change in Management Change in Directorate Resignation of Directors Appointment of Chief Financial Officer
23-May-2023	29-May-2023	Quarterly Results	Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve the Audited Financial Results for the quarter and year ended March 31 2023 Outcomes of Board Meeting and Audited Financial Results (Standalone) for the Quarter and Year ended 31st March, 2023 (As Per BSE Announcement Dated on 29.05.2023)
31-Mar-2023	31-Mar-2023	Change in Directors	Outcome of Board Meeting Appointment of Company Secretary and Compliance Officer Change in Management Reconstitution of the Committees Resignation of Chief Financial Officer Resignation of Directors
02-Feb-2023	10-Feb-2023	Quarterly Results	Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 inter alia to consider and approve the Un-Audited Financial Results for the quarter and nine months ended 31st December 2022 Outcomes of Board Meeting and Un-Audited Financial Results for the quarter ended 31.12.2022 and year to date from 01.04.2022 to 31.12. 2022 Un-Audited Financial Results for the quarter ended 31.12.2022 and year to date from 01.04.2022 to 31.12. 2022 Intimation of Appointments Appointment of Internal Auditors of the Company (As per BSE Announcement Dated on 10/02/2023)
26-Nov-2022	26-Nov-2022	Change in Directors	Outcomes of Board Meeting held on 26th November, 2022
04-Nov-2022	12-Nov-2022	Quarterly Results	Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2022 inter alia to consider and approve Un-Audited Financial Results for the quarter and six months ended September 30 2022 Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ('Company') in its meeting held today approved the Un-Audited Financial Results (Standalone) of the Company for the Quarter ended 30.09.2022 and year to date from 01.04.2022 to 30.09.2022 as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal. (As Per BSE Announcement Dated 12.11.2022) Submission of Newspaper Advertisements of the Extract of Un-Audited Financial Results approved in Board Meeting of the Company held on 12.11.2022 (As Per BSE Announcement Dated on 14.11.2022)

1 2 3